Abstract: Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.

Abstract: The present disclosure provides optimized broadly-neutralizing anti-HIV antibodies, having modified light chain variable regions and/or heavy chain variable regions leading to improved biophysical characteristics. The present disclosure also provides methods for producing these anti-HIV antibodies and methods of use thereof.

Abstract: Featured are PGDM1400 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating or curing subjects infected with HIV and/or preventing HIV infections in subjects at risk of HIV transmission using the PGDM1400 variant antibodies or fragments thereof.

Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.

Abstract: Ophthalmic formulations comprising aflibercept and a lysine salt tonicifying agent are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.

Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.

Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.

Abstract: A method of determining the activation energy Ea for degradation of a chemical species includes in sequence the steps of a) simultaneously incubating a plurality of samples of the chemical species in a single unitary device at a plurality of constant temperatures T, in each case for an incubation time t selected to result in loss of at most 20 mol % of the amount originally present; b) quenching each of the samples to stop degradation; c) determining the mole fraction m of the chemical species remaining in each of the quenched samples, relative to the amount present before incubating; d) determining for each sample a reaction rate coefficient kobs according to the equation k obs ? ( T ) = 1 - m ? ( T ) t ; and e) performing numerical regression of the kobs values obtained in step d) and the corresponding temperatures T in ° K to derive the activation energy Ea according to the following equation k obs = k 0 ? exp ? ( E a R ? ( 1 T - 1 T 0 ) ) , or t

Abstract: A method of determining the activation energy Ea for degradation of a chemical species includes in sequence the steps of a) simultaneously incubating a plurality of samples of the chemical species in a single unitary device at a plurality of constant temperatures T, in each case for an incubation time t selected to result in loss of at most 20 mol % of the amount originally present; b) quenching each of the samples to stop degradation; c) determining the mole fraction m of the chemical species remaining in each of the quenched samples, relative to the amount present before incubating; d) determining for each sample a reaction rate coefficient kobs according to the equation k obs ? ( T ) = 1 - m ? ( T ) t ; and e) performing numerical regression of the kobs values obtained in step d) and the corresponding temperatures T in ° K to derive the activation energy Ea according to the following equation k obs = k 0 ? exp ? ( E a R ? ( 1 T - 1 T 0 ) ) , or to

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Abstract: The present invention provides for an IL-1ra having reduced aggregation, methods of reducing aggregation of IL-1ra, and kits comprising an IL-1ra having reduced aggregation.

Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.

Abstract: The present invention provides for an IL-1ra having reduced aggregation, methods of reducing aggregation of IL-1ra, and kits comprising an IL-1ra having reduced aggregation.

Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.